|
⚲
|
| Keyboard |
| H Lundbeck A S
✚
|
|
|---|---|
| CIK # | 0001206828 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001206828] | |
| 4 | [0001206828] | |
| SC 13D | [0001206828] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| H Lundbeck A S | Alder Biopharmaceuticals Inc | [2019-09-26] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Enliven Therapeutics Inc | |
| H Lundbeck A S | |
| Alder Biopharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Enliven Therapeutics Inc IMRA
Common Stock
|
2020-03-16 | Conversion | 79,229 | ||
|
Enliven Therapeutics Inc IMRA
Series Seed Preferred Stock · derivative
|
2020-03-16 | Conversion | 499,069 | $0.00 | |
|
Alder Biopharmaceuticals Inc ALDR
Common Stock, par value $0.0001
|
2019-10-22 | Buy | 85,923,561 | ||
|
Alder Biopharmaceuticals Inc ALDR
Stock Option (Right to Buy) · derivative
|
2019-10-22 | Other | 0 | ||
|
Alder Biopharmaceuticals Inc ALDR
Class A-1 Convertible Preferred Stock · derivative
|
2019-10-22 | Other | 0 |